Abstract

BackgroundPatients (pts) may benefit from the use of a patient support program (PSP) to manage their rheumatoid arthritis (RA).ObjectivesTo assess the impact of PSP utilization on adalimumab (ADA) effectiveness for...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SAT0159 Impact of participation in the adalimumab patient support program on functional and clinical outcomes among patients with rheumatoid arthritis: passion study
J Kalabic ... S Wassenberg
Annals of the Rheumatic Diseases | VOL. 76
J Kalabic, et. al.J Kalabic ... S Wassenberg
01 Jun 2017
AB0262 Predictors of Patient Support Program Use Among Patients with Rheumatoid Arthritis
N Varothai ... F Van Den Bosch
Annals of the Rheumatic Diseases | VOL. 74
N Varothai, et. al.N Varothai ... F Van Den Bosch
01 Jun 2015
THU0190 Clinical outcomes among rheumatoid arthritis patients receiving adalimumab who did or did not participate in the patient support program: a subanalysis of the passion study
F Van Den Bosch ... P Zueger
Annals of the Rheumatic Diseases | VOL. 77
F Van Den Bosch, et. al.F Van Den Bosch ... P Zueger
01 Jun 2018
AB0238 USEFULNESS OF RAPID3 IN ASSESSING UNMET NEEDS OF RHEUMATOID ARTHRITIS PATIENTS FROM THE T-FLAG STUDY
K Terabe ... R Sato
Annals of the Rheumatic Diseases | VOL. 82
K Terabe, et. al.K Terabe ... R Sato
30 May 2023
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers